XML 50 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Significant Contracts (Narrative) (Details)
$ in Millions
 12 Months Ended
Oct. 01, 2018
item
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Clinical Collaboration Agreement [Member] | The University of Texas MD Anderson Cancer Center [Member]      
Supply Commitment [Line Items]      
Term of agreement 3 years    
Number of clinical studies conducted | item 4    
Clinical Collaboration Agreement [Member] | The University of Texas MD Anderson Cancer Center [Member] | Maximum [Member]      
Supply Commitment [Line Items]      
Number of patients enrolled in clinical studies | item 170    
Daiichi Sankyo [Member]      
Supply Commitment [Line Items]      
Future milestone payments payable | $   $ 10.0  
Period for which royalties will be paid following first commercial sale of licensed products   10 years  
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons   6 months  
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default   12 months  
Notice period for right of first refusal if third party to be appointed to develop or commercialize a sapacitabine-based product in Japan   60 days  
Milestones earned | $   $ 0.0 $ 0.0